Sonia Garcia

Finishing a course of TMS and feeling like yourself again brings a new worry: will it hold? How long do TMS results last, and what happens if the depression comes back? The research is more encouraging than many people expect. Among people who respond to a course, roughly half to nearly two-thirds are still responding a year later, and when symptoms do return, restarting TMS brought back the improvement for most people in the research.

‍

None of that predicts any one person's course. It does show what tends to help results last, and why the months after treatment deserve a plan of their own.

What "Lasting" Means: Response vs. Remission

Two terms do most of the work in durability research. A person has responded when their depression scores fall by at least half on a standard rating scale. They're in remission when scores drop low enough that the depression is largely gone.

‍

Durability studies then ask a narrower question than the original trials did: of the people who responded or reached remission by the end of a course, how many were still doing well months later? That framing matters when you read the numbers. A result such as 62.5% of people keeping their response for a year describes people who had already responded, not everyone who started TMS. Those follow-up checks happen at set points, typically three, six, and 12 months after a course, so durability is reported as the share of people still responding at each checkpoint.

What the Research Shows About Durability

The most direct data come from a 2014 study in The Journal of Clinical Psychiatry that followed people with medication-resistant major depression for a year after they finished TMS at 42 U.S. clinical practices. Of the 257 people who completed a course and agreed to follow-up, 120 had responded or reached remission by the end of treatment. Of those 120, 75 (62.5%) kept meeting response criteria through the full 12 months.

‍

Two details shape that result. The study used a practical approach after the course: continued antidepressant medication, plus access to more TMS if symptoms returned. And over the year, 93 participants (36.2%) had TMS reintroduced at some point, averaging about 16 treatment days. So the 62.5% reflects TMS inside ongoing care, not a single course left to stand on its own.

‍

A 2019 meta-analysis in Brain Stimulation pooled 19 studies of people who had responded to a TMS course. About two-thirds were still responding at three months, about 53% at six months, and about 46% at one year. The authors' summary: roughly half of responders keep their response for up to a year after a successful course.

‍

Read together, the two studies give a realistic range of around half to nearly two-thirds of responders still doing well a year out. The other side of those numbers matters just as much. A meaningful share of people see symptoms return within the first year, and planning for that possibility is part of good care, not a sign that treatment failed.

Factors That Influence How Long Results Last

The research has identified a few patterns, mostly at the level of groups rather than individuals:

‍

• Maintenance treatment. In the 2019 meta-analysis, studies that included maintenance treatment showed higher sustained response at some time points.
• The mix of people studied. Studies with a higher proportion of women also showed higher sustained response, a group-level pattern that says nothing reliable about any one person.
• Continued medication. The best-known durability results come from people who stayed on antidepressants after TMS, so those numbers describe that combination.
• A completed course. Durability figures come from people who finished a full acute course. They don't describe what happens after a partial one.

‍

Clinicians also weigh a person's history when planning follow-up, such as how many depressive episodes they've had and how many treatments failed before TMS. The findings above don't establish how much those factors change the odds, so they inform a clinician's judgment rather than supply a number.

Maintenance TMS: What It Is and Who May Need It

TMS maintenance treatment means periodic sessions after the main course, scheduled to protect a response rather than to answer a relapse. Schedules vary between providers and between people, and no single schedule has become standard.

‍

The evidence supports the idea without settling the details. The 2019 meta-analysis found maintenance associated with more durable response, and its authors suggested maintenance be considered in practice and tested in future trials. That's a promising signal, not a proven protocol. Maintenance TMS is also separate from staying on medication: in both the year-long and six-month studies, people continued antidepressants whether or not they received more TMS.

‍

Not everyone needs it. Some people stay well for long stretches without it. Whether maintenance makes sense for a particular person is a judgment a psychiatrist makes from their history and how they're doing in the months after the course.

Can TMS Be Repeated If Symptoms Return?

Yes, and the research on restarting TMS is among the most reassuring parts of this topic. In a six-month study in Brain Stimulation, people whose depression had improved by at least a quarter with TMS stopped treatment gradually over three weeks while starting maintenance antidepressant medication. In that study, worsening had a specific meaning: a clinician-rated decline that held for two consecutive weeks, which triggered restarting TMS. Over the next 24 weeks, 38% had symptoms worsen enough to restart TMS, and 32 of those 38 people (84%) regained their improvement. Only 10% of the 99 people whose results were reported met the study's definition of relapse.

‍

A repeat course is different from maintenance. Maintenance is planned in advance to hold a response; a repeat course starts because symptoms have come back. In the year-long study described above, about a third of participants had TMS reintroduced at some point. Whether and when to restart is a decision made with a psychiatrist, based on how symptoms are changing.

What Helps Results Last Longer

Beyond maintenance and continued medication, two more things help, though neither promises that results will last for a particular person:

‍

• Catching changes early. In the six-month study, regular assessments flagged worsening symptoms, and most people who restarted TMS at that point regained their improvement.
• Staying connected to care. Therapy and regular psychiatric visits mean someone is watching for early changes between treatments.

‍

Knowing what returning depression tends to look like makes early changes easier to catch: shifts in sleep or appetite, lower energy, less interest in usual activities, and a low mood that lingers instead of lifting after a few days. When those signs show up, reaching out sooner gives a care team more options, and our guide on how to ask for help when depressed covers how to start that conversation.

‍

These describe what research associates with better long-term results in groups of patients. They aren't instructions for any one person's treatment plan; that's a psychiatrist's call, made with the whole history in view.

Talking to a Psychiatrist About a Long-Term Plan

A TMS course is the start of a plan, not the end of one. The months afterward are when follow-up, medication decisions, and a clear plan for what happens if symptoms return matter most.

‍

At Amae, TMS sits inside our integrated care model, where psychiatric care, therapy, primary care, and peer support stay linked after the course ends. We provide TMS therapy for major depressive disorder at our Los Angeles clinic and at our Bay Area clinics in Los Altos and San Mateo. Commercial insurance plans and cash pay are both accepted, and our intake team handles prior authorization. To map out what comes after a course, talk with an Amae psychiatrist about a long-term plan. Anyone in crisis can reach the 988 Suicide and Crisis Lifeline by call or text.

Frequently Asked Questions

How long do TMS results typically last?

For many people, months to a year or longer, though it varies. In a year-long study of people who responded to TMS, 62.5% kept meeting response criteria for the full 12 months. A 2019 meta-analysis found that about half of responders were still responding at one year.

What percentage of people relapse after TMS?

Some return of symptoms within a year is common. In the 2019 meta-analysis, roughly half of responders were no longer responding at one year. That isn't always a full relapse: in a six-month study, 38% had symptoms worsen enough to restart TMS, while 10% met the study's definition of relapse.

Can TMS be repeated if depression comes back?

Yes. In a six-month study, 84% of people whose symptoms worsened regained their improvement when TMS was restarted. A repeat course is different from ongoing maintenance sessions, and the decision is made with a psychiatrist based on individual history.

Do I need maintenance TMS sessions after my initial course?

Not necessarily. Some people stay well without them, and there is no standard maintenance schedule across providers. Research links maintenance with longer-lasting response, so whether it fits is a decision a psychiatrist makes based on your response and how closely symptoms are being monitored.

What can help TMS results last longer?

The research points to planned follow-up, continued medication when it's part of the plan, and catching symptom changes early. These are general findings from groups of patients, not instructions for any one person's treatment.

Is maintenance TMS covered by insurance?

It depends on the insurer and on whether sessions are billed as maintenance or as a new course for returning symptoms, since coverage can differ between the two. Ask the provider to verify benefits with your insurer before sessions begin.

‍

Citations

1. Dunner DL, Aaronson ST, Sackeim HA, et al. A multisite, naturalistic, observational study of transcranial magnetic stimulation for patients with pharmacoresistant major depressive disorder: durability of benefit over a 1-year follow-up period. Journal of Clinical Psychiatry. 2014;75(12):1394-1401. https://pubmed.ncbi.nlm.nih.gov/25271871/ (Tier 1)
2. Senova S, Cotovio G, Pascual-Leone A, Oliveira-Maia AJ. Durability of antidepressant response to repetitive transcranial magnetic stimulation: systematic review and meta-analysis. Brain Stimulation. 2019;12(1):119-128. https://pubmed.ncbi.nlm.nih.gov/30344109/ (Tier 1)
3. Janicak PG, Nahas Z, Lisanby SH, et al. Durability of clinical benefit with transcranial magnetic stimulation (TMS) in the treatment of pharmacoresistant major depression: assessment of relapse during a 6-month, multisite, open-label study. Brain Stimulation. 2010;3(4):187-199. https://pubmed.ncbi.nlm.nih.gov/20965447/ (Tier 1)
4. 988 Suicide and Crisis Lifeline. https://988lifeline.org (Tier 2)

‍

Does TMS therapy work? For many people whose depression has not responded to antidepressants, yes, and the research shows how many. The FDA cleared transcranial magnetic stimulation (TMS) for major depressive disorder in 2008 on the strength of sham-controlled trials, and more than a decade of real-world outcome data has followed. What the evidence does not support is an unqualified "TMS works." Outcomes vary from person to person, the numbers depend on how you define success, and the people who benefit most share a recognizable profile.

‍

Start with the definitions, because every statistic below depends on them.

What "Works" Means: Response vs. Remission

Depression research measures success on rating scales, and two thresholds matter.

‍

Response means a meaningful reduction in symptoms, usually defined as a 50% or greater drop in the score on a standard depression scale. Someone who responds feels noticeably better but may still have symptoms.

‍

Remission means the score falls below the scale's cutoff for depression. Symptoms are largely gone. Remission is the goal of treatment, and it is the harder bar to clear.

‍

Two more details shape every TMS success rate you will read. The scale matters: clinician-rated scales and patient questionnaires produce different numbers for the same group of people. And the population matters. TMS is studied almost entirely in people whose depression has already failed to respond to medication, so its rates should be compared with other treatments for that same group, not with a first antidepressant.

What the Clinical Evidence Shows

One of the key trials confirming TMS's effect was a randomized, sham-controlled study led by Mark George and published in Archives of General Psychiatry in 2010. It enrolled 199 adults with major depression who were not taking antidepressants, with 190 included in the analysis. During the blinded phase, 14.1% of people receiving active TMS reached remission, compared with 5.1% receiving sham stimulation. The odds of remission were 4.2 times higher with real treatment, and the number needed to treat was 12.

‍

Those figures look modest next to many TMS marketing pages. The blinded phase was short, the remission bar strict, and a sham-controlled design exists to prove an effect is real, not to show the best a treatment can do in practice. On that goal, it succeeded.

‍

Real-world outcomes come from a different kind of study. In 2012, Linda Carpenter and colleagues published a multisite observational study in Depression and Anxiety covering 307 outpatients treated at 42 clinical TMS practices across the United States. These patients had already tried an average of 2.5 antidepressants at adequate dose and duration without satisfactory improvement. By the end of treatment, 58% had responded and 37.1% were in remission on the clinician-rated scale. On the PHQ-9, a self-report questionnaire, 56.4% responded and 28.7% reached remission.

‍

Our own framing for patients is deliberately conservative: roughly half of people respond and roughly one in three reach remission, and those figures describe people who had not benefited from four or more antidepressants. So how effective is TMS for depression? For depression that has resisted medication, it helps about half of the people who complete a standard course, and it clears depression for about a third.

‍

One clarification about higher numbers you may have seen. Remission rates of 70% or 80% come from newer accelerated protocols, many sessions per day over about a week guided by brain imaging, in small early trials. The FDA has cleared a rapid-acting form of TMS, as the National Institute of Mental Health notes, but we do not offer accelerated protocols, and the figures in this article describe the standard daily course our clinics provide.

TMS Compared to Other Depression Treatments

Antidepressant medication remains first-line, and TMS is typically considered after it. Compared with switching to yet another medication, TMS acts on the brain directly rather than through the bloodstream, which is why it does not cause weight gain, sexual side effects, or sedation.

‍

Electroconvulsive therapy (ECT) produces larger and faster symptom reduction in head-to-head research, but it requires general anesthesia and can affect memory around the time of treatment, so it is reserved for severe or urgent situations. Esketamine (Spravato) and ketamine can act within days rather than weeks, with a different monitoring burden and a different side-effect profile. None of these is universally better. They suit different clinical pictures, and we compare each pairing in depth in dedicated articles.

Who Is Most Likely to Benefit

The evidence points to a consistent profile of the person who does well with TMS. It matches the eligibility criteria we use, which also track what insurers require for authorization:

‍

• A confirmed diagnosis of major depressive disorder. TMS is cleared for MDD, not for every kind of low mood, and getting the diagnosis right comes first. If you are unsure how your diagnosis fits, our guide to major depressive disorder vs. persistent depressive disorder explains the distinction.
• Multiple antidepressants from different classes that did not bring adequate improvement.
• Psychotherapy that was tried and did not bring enough relief.
• No medical contraindications. TMS uses a strong magnetic field, so we screen for a history of seizures or epilepsy, metal in the head outside the mouth, implanted devices such as pacemakers, and a history of stroke, neurosurgery, or brain injury. Pregnancy calls for individualized planning with your obstetric and psychiatric team. Ordinary dental fillings are not a problem.
• The ability to commit to a daily session schedule for several weeks.

‍

Notice what is not on the list: how many years you have spent on medication. More than half of the Carpenter study's patients responded after multiple failed medication trials.

How Long It Takes to See Results

TMS is cumulative. A single session produces nothing you would notice; the benefit builds as repeated stimulation changes activity in the mood circuits being targeted. At our clinics, a full course of TMS means 20 to 30 weekday sessions over roughly four to six weeks.

‍

When improvement shows up varies. Some people notice sleep, energy, or concentration shifting in the second or third week, often before their mood lifts. Others feel little change until the final stretch of the course. Both patterns are normal, and neither predicts the final outcome well, which is why progress is judged with symptom rating scales rather than a mid-course impression. The most common mistake is writing TMS off after a handful of sessions.

What Happens If TMS Doesn't Work?

It is a fair question to ask before you start, and the answer is not "you are out of options."

‍

If symptom scores have not moved by the later part of the course, a psychiatrist reassesses rather than simply stopping. The treatment plan can be adjusted, including the stimulation parameters or the length of the course. Medication can be changed or added, since TMS and medication are often combined. Psychotherapy can be intensified. And other options for treatment-resistant depression remain on the table, including esketamine and, for severe or urgent depression, ECT.

‍

Partial response is its own category: a 30% drop in symptoms is not a treatment failure, and it often shapes what comes next. People who responded well to a first course can also be treated again if depression returns.

‍

What happens if TMS doesn't work is, in the end, what happens at every stage of treating difficult depression: the plan changes, and the person stays in care. If you are having thoughts of suicide at any point, call or text 988 to reach the Suicide and Crisis Lifeline.

What TMS Does Not Do

TMS is a specific tool, and its limits are as well defined as its strengths.

‍

It does not work for everyone. About half of people with medication-resistant depression respond, which means about half do not.

‍

It is not a first-line treatment. In practice, and in insurers' criteria, TMS comes after antidepressant trials, not instead of them.

‍

It is not a general-purpose brain treatment. The FDA clearances are specific: major depressive disorder since 2008 and obsessive-compulsive disorder since 2018, plus a small number of narrowly defined uses. Anxiety disorders and PTSD are being studied, but those uses are not cleared. At our clinics we currently provide TMS for major depressive disorder.

‍

It is not a cure. Remission is a realistic goal, but depression can return, and TMS belongs inside ongoing care rather than serving as a one-time fix.

What to Expect During a Course of Treatment

The practical side is simpler than most people expect.

‍

Treatment begins with a screening visit of 30 to 60 minutes to confirm the diagnosis, review your treatment history, and check for contraindications. Sessions then run Monday through Friday, 30 to 40 minutes each. You sit in a chair, awake, while a magnetic coil rests against your scalp and delivers pulses in short trains. It feels like tapping. With no anesthesia or sedation, you drive yourself home and go straight back to your day.

‍

Side effects are mostly local and mostly early: scalp discomfort at the coil site and headache, both of which typically clear within the first week. Because nothing enters your bloodstream, TMS does not cause the weight gain, sexual dysfunction, stomach upset, dry mouth, or sedation that antidepressants can. The one serious risk, seizure, is exceedingly rare, and the screening process exists to keep it that way.

Talking to a Psychiatrist About Whether TMS Is Right for You

Population statistics tell you what TMS does for people like you. They cannot tell you what it will do for you. That question gets answered in an evaluation, where a psychiatrist reviews your diagnosis, medication history, health, and goals, and tells you plainly whether TMS is a reasonable next step.

‍

At Amae, TMS is one part of an integrated care model in which psychiatry, therapy, primary care, and peer support come from the same team, so a course of TMS fits into your broader care rather than running alongside it. We provide it in Los Angeles, Los Altos, and San Mateo, all commercial insurance plans are accepted alongside cash pay, and prior authorization is handled by our intake team. To find out where you stand, schedule an evaluation with an Amae psychiatrist.

Frequently Asked Questions

What percentage of people does TMS work for?

In a major multisite real-world study, 58% of patients responded and 37% reached remission on clinician ratings after a standard course. Those patients had already tried an average of 2.5 antidepressants without adequate relief, so the numbers describe treatment-resistant depression, not depression in general. Our own conservative framing is that about half respond and about one in three reach remission.

How soon does TMS start working?

Gradually, over the course rather than after a single session. Some people notice changes in sleep, energy, or focus within the first two or three weeks, while others see improvement only near the end of the four-to-six-week course. Neither pattern reliably predicts the final result.

Does TMS work for everyone?

No. Like every treatment for depression, TMS produces a range of outcomes, and roughly half of people with medication-resistant depression do not respond. That is why a psychiatrist tracks symptoms during the course and adjusts the plan if progress stalls.

Is TMS FDA-approved or still experimental?

TMS is FDA-cleared, not experimental. Clearance for major depressive disorder came in 2008 and for obsessive-compulsive disorder in 2018, both on the basis of controlled clinical trials. Uses such as anxiety disorders and PTSD are still at the research stage and are not cleared.

What happens if TMS doesn't work for me?

A psychiatrist reassesses and lays out next steps. Those can include adjusting the treatment plan, combining TMS with medication changes or psychotherapy, or considering other treatment-resistant depression options such as esketamine or ECT. Not responding to TMS does not mean nothing else will work.

How long do the effects of TMS last?

It varies. Improvement often lasts well beyond the end of the course, some people need a maintenance plan or a repeat course, and the timing differs from person to person. Durability deserves its own discussion, and it is one to have with your psychiatrist as you approach the end of a course.

‍

Citations

1. George MS, Lisanby SH, Avery D, et al. Daily left prefrontal transcranial magnetic stimulation therapy for major depressive disorder: a sham-controlled randomized trial. Archives of General Psychiatry. 2010. https://pubmed.ncbi.nlm.nih.gov/20439832/ (Tier 1)
2. Carpenter LL, Janicak PG, Aaronson ST, et al. Transcranial magnetic stimulation (TMS) for major depression: a multisite, naturalistic, observational study of acute treatment outcomes in clinical practice. Depression and Anxiety. 2012. https://pubmed.ncbi.nlm.nih.gov/22689344/ (Tier 1)
3. Micallef-Trigona B. Comparing the effects of repetitive transcranial magnetic stimulation and electroconvulsive therapy in the treatment of depression: a systematic review and meta-analysis. Depression Research and Treatment. 2014. https://pubmed.ncbi.nlm.nih.gov/25143831/ (Tier 1)
4. National Institute of Mental Health. Brain Stimulation Therapies. https://www.nimh.nih.gov/health/topics/brain-stimulation-therapies/brain-stimulation-therapies (Tier 2)
5. 988 Suicide and Crisis Lifeline. https://988lifeline.org (Tier 2)

‍

f you are comparing TMS, ketamine, and Spravato for depression, you have probably reached the point where standard antidepressants have not done enough. All three are evidence-based options for treatment-resistant depression, and beyond that they have little in common. TMS is a course of magnetic stimulation delivered while you sit awake in a chair. Ketamine is an anesthetic given by IV, used off-label for depression. Spravato is a nasal spray made from esketamine, one of the two mirror-image forms that make up ketamine, with its own FDA approval and its own rulebook.

‍

None of the three is universally better. They differ in mechanism, speed, setting, and monitoring, and the right one depends on your clinical history and how you respond. Treatment-resistant depression generally means depression that has not adequately improved after at least two antidepressants taken at a proper dose for long enough, and that is the group where all three are most often used.

What Is TMS?

Transcranial magnetic stimulation uses a coil placed against the scalp to deliver focused magnetic pulses to the left dorsolateral prefrontal cortex, a region involved in mood regulation. The FDA first cleared TMS for major depressive disorder in 2008, according to the National Institute of Mental Health. It is delivered in an office, with no anesthesia and no medication.

‍

Our standard TMS course runs 20 to 30 daily sessions over four to six weeks, each 30 to 40 minutes long. You stay awake throughout and drive yourself home afterward. In real-world outcome data from 42 U.S. practices, more than half of patients with medication-resistant depression responded to a standard course, and more than a third reached remission.

What Is Ketamine Therapy?

Ketamine has been an FDA-approved anesthetic since 1970. Its use for depression is off-label: prescribed for a purpose the FDA has not formally approved, which is legal and common in medicine but leaves the safeguards less standardized. It is usually given as an IV infusion in a monitored clinic, as a series of sessions over a few weeks.

‍

Ketamine blocks the NMDA receptor, a glutamate receptor, rather than acting on serotonin like standard antidepressants, and that difference is thought to explain its speed. In a landmark 2006 trial, 18 people with treatment-resistant depression received a single infusion of 0.5 mg/kg, and their symptoms improved significantly within 110 minutes. By the next day, 71% had responded and 29% were in remission. One week later, 35% still met the response threshold. Rapid, real, and often short-lived.

‍

The catch is in the monitoring. Ketamine causes dissociation, a sense of detachment from your body or surroundings, plus sedation and blood pressure rises during and after the infusion, so you are observed until those effects pass and cannot drive that day. In a 2017 consensus statement in JAMA Psychiatry, an American Psychiatric Association task force found the evidence for rapid antidepressant effects convincing but the studies small, the longer-term efficacy data lacking, and the safety data on repeated dosing limited.

What Is Spravato (Esketamine)?

Ketamine is a mixture of two mirror-image molecules. Spravato is esketamine, one of those two, delivered as a nasal spray. Unlike IV ketamine, it has FDA approval for depression. The original approval came in March 2019 for treatment-resistant depression alongside an oral antidepressant, a second indication followed for adults with major depressive disorder and acute suicidal thoughts or behavior, and in January 2025 the FDA approved Spravato as a standalone monotherapy for treatment-resistant depression, with no oral antidepressant required, per the current prescribing information.

‍

That approval comes with a rulebook. Spravato can only be given at a setting certified under a Risk Evaluation and Mitigation Strategy (REMS) program: you take the spray under supervision, you are monitored for at least two hours before an assessment clears you to leave, and you cannot drive until the next day after a restful sleep. Its label carries a boxed warning for sedation, dissociation, respiratory depression, abuse and misuse, and suicidal thoughts and behaviors in younger patients.

‍

So is Spravato the same as ketamine? Related, not identical: same molecular family, same receptor, similar rapid onset and dissociative effects, but a different route, a formal FDA indication, and mandatory monitoring rules that off-label ketamine does not carry. For most people comparing TMS vs Spravato, those rules and insurance coverage are the practical differences that matter.

TMS vs Ketamine vs Spravato: Side-by-Side Comparison

Onset and Duration of Effect

Speed is the clearest dividing line. TMS builds gradually, and many people do not notice a clear change until the second or third week or later. Ketamine and Spravato can shift symptoms within hours to days.

‍

Speed and staying power are different things. Ketamine's effect after a single infusion often fades within a week or two, which is why it is given as a series with maintenance dosing. Spravato starts at twice a week and tapers, with the need for continued treatment reassessed along the way. Research on durability is still developing for all three, and none should be described as permanent.

Side Effects and Safety Considerations

TMS side effects are local and short-lived: scalp discomfort where the coil sits, headache, and sometimes brief lightheadedness or facial muscle twitching during the pulses. These usually settle within the first week, and because nothing enters the bloodstream there is no weight gain, sexual dysfunction, or sedation. Seizure is the one serious risk, exceedingly rare, and TMS is not used in people with a seizure history, metal in the head, or implanted electronic devices.

‍

Ketamine and Spravato share a different profile. The most common reactions to Spravato in trials were dissociation, dizziness, nausea, sedation, vertigo, numbness, anxiety, lethargy, increased blood pressure, vomiting, feeling drunk, and headache. Those effects peak in the hours after dosing, which is what the monitoring window is for, and both drugs carry a potential for misuse that shapes who is a candidate. Each option has its own screening, and a contraindication to one does not rule out the others.

Cost and Insurance

For TMS, most commercial insurers cover treatment for major depressive disorder once eligibility criteria are met, typically a confirmed diagnosis and documented antidepressant trials without adequate relief. Prior authorization is standard. For TMS we take all commercial insurance plans, cash pay is available, and authorization is something our intake team manages for you.

‍

Spravato is more commonly covered than off-label ketamine because it has an FDA indication insurers can write criteria around, though prior authorization and documentation of failed antidepressant trials are typically required. Ketamine infusion coverage varies widely, and many clinics are self-pay. Published cost estimates vary so much by dose, frequency, and insurance status that a single dollar figure would mislead; ask each provider and your insurer directly.

Can These Treatments Be Combined?

Sometimes, and the research is early. A 2024 systematic review found six published studies on combining TMS with ketamine, mostly case reports plus one retrospective review and one small pilot, and reported substantial and sustained improvement with generally mild side effects. The authors also said the designs were too varied and the samples too small for firm conclusions, and called for randomized trials.

‍

In practice, TMS and Spravato are sometimes used one after the other. Combining any of these is a clinical judgment a psychiatrist makes from your history, not a general recommendation, and the more common pattern is to use one, assess the response, then decide.

Choosing Between Them: What Influences the Decision

A psychiatrist weighing these options usually works through a short list:

‍

• Treatment history. Which antidepressants, at what doses, for how long, and whether psychotherapy has been tried.
• How urgently relief is needed. When symptoms are severe or suicidal thoughts are present, a faster-acting option may take priority, alongside care for suicidal thoughts.
• Tolerance for the experience. Dissociation and a two-hour monitored window, versus a daily half-hour appointment for several weeks with no drug effects.
• Practical constraints. Whether you can get to daily sessions, whether someone can drive you home after Spravato or ketamine, and what your insurance will authorize.
• Health factors. Seizure history, metal implants, blood pressure, and any history of substance misuse each rule options in or out.
• What else is in place. Any of the three works better inside ongoing psychiatric care and therapy than as a standalone fix.

Making the Decision With an Integrated Care Team

TMS, ketamine, and Spravato are tools, and tools do their best work inside a plan: a psychiatrist who knows your history, a therapist working alongside the biological treatment, and a team that notices when the plan needs to change.

‍

That is how we work. At Amae, our one-team care model combines psychiatry, therapy, primary care, and peer support, and TMS and Spravato are available through our Los Angeles and Bay Area clinics as part of that care. If you have been through the antidepressant cycle and want a clear, unhurried look at what comes next, talk with an Amae psychiatrist about your options. If you are in crisis or thinking about suicide, call or text 988 now.

Frequently Asked Questions

What is the difference between TMS and ketamine for depression?

TMS stimulates the brain with magnetic pulses over a course of daily outpatient sessions, with no drug, no sedation, and no monitoring afterward. Ketamine is a medication that acts on NMDA receptors, given by infusion or, as esketamine, by nasal spray, with monitored sedation and dissociation and often faster but shorter-lived effects.

Is Spravato the same as ketamine?

Related but not identical. Spravato is esketamine, the S-enantiomer of the ketamine molecule, delivered as an FDA-approved nasal spray under a required monitoring program. Ketamine infusions use the full ketamine compound and are prescribed off-label for depression, without an FDA indication for that use.

Is Spravato only approved with an antidepressant?

Not anymore. The original 2019 approval was for use alongside an oral antidepressant, and in January 2025 the FDA also approved Spravato as a standalone monotherapy for adults with treatment-resistant depression. Whether it is used alone or with an antidepressant is a decision your psychiatrist makes based on your situation.

Which works faster, TMS or Spravato?

Spravato. Esketamine and ketamine can produce symptom change within hours to days, while TMS builds gradually across a four-to-six-week course. Faster onset does not mean more durable improvement, and both durability and side effects belong in the comparison.

Can TMS and Spravato be used together?

Sometimes, as a clinical decision made with a psychiatrist based on your individual history. Both can be part of a broader treatment-resistant depression plan alongside medication and therapy, and the evidence on combining them is still early.

Is ketamine or Spravato covered by insurance?

Spravato is more commonly covered, because it has an FDA indication insurers can build criteria around, though prior authorization and proof of failed antidepressant trials are usually required. Coverage for off-label ketamine infusions varies widely and is often self-pay. Confirm with the provider and your insurer before starting.

‍

Citations

1. National Institute of Mental Health. Brain Stimulation Therapies. https://www.nimh.nih.gov/health/topics/brain-stimulation-therapies/brain-stimulation-therapies (Tier 2)
2. Carpenter LL, Janicak PG, Aaronson ST, et al. Transcranial magnetic stimulation (TMS) for major depression: a multisite, naturalistic, observational study of acute treatment outcomes in clinical practice. Depression and Anxiety. 2012. https://pubmed.ncbi.nlm.nih.gov/22689344/ (Tier 1)
3. Zarate CA, Singh JB, Carlson PJ, et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Archives of General Psychiatry. 2006. https://pubmed.ncbi.nlm.nih.gov/16894061/ (Tier 1)
4. Sanacora G, Frye MA, McDonald W, et al. A consensus statement on the use of ketamine in the treatment of mood disorders. JAMA Psychiatry. 2017. https://pubmed.ncbi.nlm.nih.gov/28249076/ (Tier 1)
5. U.S. Food and Drug Administration. Drugs@FDA: SPRAVATO (esketamine), NDA 211243, approval history. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211243 (Tier 2)
6. U.S. Food and Drug Administration. SPRAVATO (esketamine) nasal spray prescribing information, revised January 2025. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/211243s016lbl.pdf (Tier 2)
7. Arubuolawe OO, Folorunsho IL, Busari AK, et al. Combination of transcranial magnetic stimulation and ketamine in treatment-resistant depression: a systematic review. Cureus. 2024. https://pubmed.ncbi.nlm.nih.gov/39156335/ (Tier 1, small-study review)
8. 988 Suicide and Crisis Lifeline. https://988lifeline.org (Tier 2)

‍